Human Polyclonal Antibody to Treat Unvaccinated Non-Hospitalized Adult Patients

Translate to Spanish or other 102 languages!

Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. Image for illustration purposes.
Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. Image for illustration purposes.

Mega Doctor News

- Advertisement -

EDINBURG, Texas – DHR Health is involved in a new and innovative study to use human polyclonal antibody to treat non-hospitalized patients who are >18 years of age with mild-moderate COVID-19. Safety of this human polyclonal antibody (SAB-185) has already been established. This would be the first such study in which human polyclonal antibodies will be used to treat patients with COVID-19.

“We are embarking on a new study that is FDA-approved and NIH-funded to infuse human polyclonal antibodies in non-hospitalized unvaccinated high-risk individuals who are COVID-19 positive” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “The human polyclonal antibody has been shown to neutralize both wild-type and various variants of SARS-CoV-2 virus including Delta. the primary objective of this study is to prevent hospitalization of the patients with COVID-19.”

The study entails a single treatment with either REGEN-COV monoclonal antibody or SAB-185 human polyclonal antibody which is infused intravenously. Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. To learn more about who would qualify for this treatment, please visit this weblink: https://youtu.be/u8lubUkucNY or call COVID-19 treatment hotline (956) 362-2393 (9:00 a.m. – 5:00 p.m.; M-F) or (956) 342-2383 for more information.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Mayo Clinic Study Sheds New Light on Memory Loss

A new framework, published in Brain, could reshape researchers' understanding of how the brain creates memories and experiences, and how disruptions in this process may indicate Alzheimer’s disease and other forms of dementia.

United States and Mexico Lose Measles Elimination Status Amid Continued Outbreaks

The United States, Mexico and Bolivia have lost their measles elimination status after the highly contagious virus circulated continuously for more than 12 months, the Pan American Health Organization (PAHO) announced November 17, 2026.

Eating and sleeping later associated with increased health risks

Staying up late and eating later in the evening could increase the risk of metabolic syndrome, a term that refers to conditions that increase the risk of type 2 diabetes, cardiovascular disease, and high cholesterol.

Health Officials Release Joint Statement Regarding Loss of U.S. Measles Elimination Status

CDC and its partners are committed to stopping measles outbreaks, protecting Americans, and regaining measles elimination status.
- Advertisement -